Actively Recruiting
Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.
Led by Qilu Hospital of Shandong University · Updated on 2026-01-30
266
Participants Needed
1
Research Sites
312 weeks
Total Duration
On this page
Sponsors
Q
Qilu Hospital of Shandong University
Lead Sponsor
T
The Second Hospital of Shandong University
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the clinical efficacy of using tumor organoid drug sensitivity experiments to guide postoperative adjuvant chemotherapy in patients with muscle-invasive bladder cancer, and to assess the application value of tumor organoid drug sensitivity experiments in guiding individualized postoperative adjuvant chemotherapy for muscle-invasive bladder cancer.
CONDITIONS
Official Title
Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years, any gender
- Undergoing radical cystectomy with tissue available for organoid culture
- Diagnosed with pT3-pT4 and/or lymph node-positive muscle-invasive bladder cancer
- Able to tolerate platinum-based chemotherapy
- ECOG performance status between 0 and 2
- Able to comply with study procedures and follow-up as judged by the investigator
- Willing and able to provide informed consent to participate in the study
You will not qualify if you...
- Severe, life-threatening complications after radical cystectomy, such as cardiovascular issues, renal failure, respiratory failure, liver failure, sepsis, pulmonary embolism, or major bleeding
- Immunodeficiency or receiving immunosuppressants or radiotherapy
- Known allergies to study drugs or related substances
- Long-term corticosteroid use or history of drug abuse
- Planning pregnancy, currently pregnant, or breastfeeding
- Abnormal blood counts or liver/kidney function beyond specified limits
- History of myelodysplastic syndrome or acute myeloid leukemia
- Neurological or psychiatric disorders such as epilepsy or dementia
- Serious comorbid conditions affecting safety or study completion
- Uncontrolled infections, heart failure, unstable angina, or arrhythmias
- Investigator judgment deeming participant unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qilu Hospital of Shandong University
Jinan, Shandong, China
Actively Recruiting
Research Team
J
Jun Chen
CONTACT
J
Jingchao Liu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here